Medication Guides35 min readUpdated 2026-04-28
Survodutide: Phase 3 Results & FDA Status 2026
Survodutide Phase 3: up to 16.6% weight loss at 76 weeks (SYNCHRONIZE-1, April 2026). FDA status, approval timeline, clinical trials, and what to do now.
Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.
Takes 60 seconds · Free · No signup